Testosterone ineffective as treatment for ejaculatory dysfunction

Low T1 Testosterone ineffective as treatment for ejaculatory dysfunction Testosterone replacement therapy doesn’t benefit men with ejaculatory dysfunction, according to a study published in the July 9 issue of The Journal of Clinical Endocrinology & Metabolism.

Testosterone treatments are used to increase the hormone levels in men with hypogonadism, a condition in which men do not produce enough testosterone due to injury or disease. The condition can cause symptoms such as low sex drive, muscle loss and fatigue.

Ejaculatory dysfunction includes conditions such as delayed ejaculation, premature ejaculation and anejaculation.

There is limited data to indicate whether testosterone deficiency may be a contributor to ejaculatory dysfunction in men. But researchers say little is known about the condition and why testosterone therapy has failed to benefit patients with ejaculatory dysfunction.

The randomized trial involved 76 men with symptoms of ejaculatory dysfunction. Those who took a 60 mg of testosterone 2% daily for 16 weeks reported a better score on a survey questioning ejaculatory function after treatment, but that number wasn’t significantly different from scores reported by men who received a placebo. There were also no differences between the two groups for ejaculate volume, orgasmic function, or ratings for satisfaction/bother.

Prescriptions for testosterone therapy have skyrocketed in recent years thanks to aggressive marketing campaigns targeting men to ask their doctors if they have “Low T” and may be candidates for testosterone treatment. Studies show it has led to overprescribing of testosterone products such as Androgel, Axiron and Testim. This is concerning. Testosterone therapy has been linked to an increased risk of heart attacks, strokes, and deaths.

Makers of testosterone therapies are facing lawsuits that claim the companies knew the synthetic hormones posed cardiovascular risks but failed to adequately warn doctors or their patients, instead spending millions to market the products directly to men.

Source: MedPage Today